Sicherheitsstudie zu Idarucizumab bei Kindern und Jugendlichen, die Dabigatranetexilat bekommen.

Drug: Idarucizumab

Inclusion criteria:

Patients taking dabigatran etexilate in the paediatric trials 1160.106 or 1160.108 are
eligible for this trial if they meet the following criteria:

Group A:

- Overt bleeding judged by the treating physician to require a reversal agent.

- Currently taking dabigatran etexilate in the context of a clinical trial with
dabigatran etexilate (1160.106 or 1160.108).

- Male or female patients from 0 to less than 18 years of age at the time of informed
consent/assent for participation in trial 1160.106 or in trial 1160.108.

- Female patients of childbearing potential (defined as having experienced menarche)
must have followed the contraception requirements according to the dabigatran trial
1160.106 or trial 1160.108 in which they are enrolled.

- Written informed consent provided by the patient (and/or the patient's legally
accepted representative) and assent provided by the patient (if applicable) at the
time of informed consent signature in accordance with Good Clinical Practice (GCP) and
local legislation prior to admission to the trial. If the child is unable to give
assent at the time of the emergency, the assent, when applicable will be obtained as
soon as feasible.

Group B:

- A condition requiring an emergency surgery or invasive procedure where adequate
haemostasis is required. Emergency is defined as need for surgery or intervention
within the following 8 hours.

- Currently taking dabigatran etexilate in the context of a clinical trial with
dabigatran etexilate (1160.106 or 1160.108).

- Male or female patients from 0 to less than 18 years of age at the time of informed
consent/assent for participation in trial 1160.106 or in trial 1160.108.

- Female patients of childbearing potential (defined as having experienced menarche)
must have followed the contraception requirements according to the dabigatran trial
1160.106 or trial 1160.108 in which they are enrolled.

- Written informed consent provided by the patient (and/or the patient's legally
accepted representative) and assent provided by the patient (if applicable) at the
time of informed consent signature in accordance with GCP and local legislation prior
to admission to the trial. If the child is unable to give assent at the time of the
emergency, the assent, when applicable will be obtained as soon as feasible.

Exclusion criteria:

Group A:

- Patients with minor bleeding (e.g. epistaxis, haematuria) who can be managed with
standard supportive care.

- Patients with no clinical signs of bleeding.

- Patients with body weight < 2.5 kg

- Contraindications to trial medication including known hypersensitivity to the drug or
its excipients; i.e. patients with hereditary fructose intolerance who may react to
sorbitol.

- Female patients who are pregnant, nursing, or who plan to become pregnant while in the
trial.

Group B:

- A surgery or procedure which is elective or where the risk of uncontrolled or
unmanageable bleeding is low.

- Patients with body weight < 2.5 kg

- Contraindications to trial medication including known hypersensitivity to the drug or
its excipients; i.e. patients with hereditary fructose intolerance who may react to
sorbitol.

- Female patients who are pregnant, nursing, or who plan to become pregnant while in the
trial.